This Medical Marijuana News Has GW Pharmaceuticals Plc Soaring

Jacob Redmond

Well-Known Member
What: GW Pharmaceuticals, Plc. (NASDAQ: GWPH ) shares jumped 19% higher earlier this week following news that a presentation outlining the benefits of its clinical stage marijuana-based drug Epidiolex would be given at a key industry conference next week.

So What: The data that will be presented at the American Academy of Neurology conference on April 22nd reflects findings from a physician-led expanded access program that provides Epidiolex to patients suffering from a variety of tough-to-treat forms of epilepsy.

Specifically, the data suggests that patients taking Epidiolex for at least 12-weeks suffered up to 52% fewer seizures.

Overall, results were based on 137 patients, whose condition was inadequately controlled by existing medication, including patients diagnosed with both Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy.

Now What: The results appear to be encouraging for GW Pharmaceuticals' current epilepsy research program.

The company launched two phase 3 studies evaluating Epidiolex in Dravet syndrome patients earlier this year, and it plans to launch additional studies in Lennox-Gastaut syndrome patients by year's end. Results from the Dravet syndrome trial should be available by the end of 2015, and the Lennox-Gastaut data will follow in 2016.

If those trials are successful, it could mark a significant step forward for GW Pharmaceuticals' marijuana research program; however, investors should know that the company already boasts a market cap $2.15 billion. That's a pretty rich valuation for a company that generates little revenue (so far). As a result, I'm hesitant to chase this one higher.

21928.jpg


News Moderator: Jacob Redmond 420 MAGAZINE ®
Full Article: This Medical Marijuana News Has GW Pharmaceuticals Plc Soaring (GWPH)
Author: Todd Campbell
Contact: Fool.com: Stock Investing Advice | Stock Research
Photo Credit: None Found
Website: Fool.com: Stock Investing Advice | Stock Research
 
Back
Top Bottom